NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
18 janv. 2024 00h21 HE
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...
UK’s Psychiatrist-Led Diverse Diagnostics Offers Private ADHD Assessment with Free Consultations
12 janv. 2024 09h00 HE
|
Diverse Diagnostics
Glasgow, United Kingdom, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Diverse Diagnostics, a leading psychiatric clinic based in the United Kingdom, announces the launch of its specialised service offering...
Done. Reaches Milestone in Opening 30 Physical Clinic Locations
04 déc. 2023 09h00 HE
|
Done.
San Francisco, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Done., a patient-first startup established by a team of experts dedicated to supporting the millions of adults facing the ADHD and mental health...
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
13 nov. 2023 16h15 HE
|
Cingulate Inc.
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE...
Cingulate to Host CNS Key Opinion Leader Panel in New York City
17 oct. 2023 14h22 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
03 oct. 2023 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical...
Cingulate Inc. to Present at the LD Micro Main Event XVI
21 sept. 2023 13h30 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Announces Closing of $4.0 Million Public Offering
13 sept. 2023 16h15 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate Announces Pricing of $4.0 Million Public Offering
11 sept. 2023 09h22 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary...
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
11 sept. 2023 06h00 HE
|
Cingulate Inc.
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend...